NASDAQ:QTNT

Quotient Stock Forecast, Price & News

$4.71

+0.07 (+1.51 %)

(As of 10/23/2020 12:00 AM ET)

Add

Compare

Today's Range

$4.58

Now: $4.71▼

$4.75

50-Day Range

$4.38

MA: $5.18▼

$5.72

52-Week Range

$2.39

Now: $4.71▼

$10.38

Volume20,695 shs

Average Volume831,859 shs

Market Capitalization$379.83 million

P/E RatioN/A

Dividend YieldN/A

Beta2.3

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company is also developing microarray-based SARS-CoV-2 antibody test for use on the MosaiQ platform for COVID-19. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Quotient has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.50, Quotient has a forecasted upside of 186.6% from its current price of $4.71.
Amount of Analyst Coverage
Quotient has only been the subject of 1 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Quotient has received 294 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Quotient has received 312 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Quotient has received 51.49% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Quotient and other stocks. Vote “Outperform” if you believe QTNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QTNT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Quotient does not currently pay a dividend.
Dividend Growth
Quotient does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Quotient insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,374,997.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 12.30% of the stock of Quotient is held by insiders.
Percentage Held by Institutions
77.64% of the stock of Quotient is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Quotient are expected to grow in the coming year, from ($1.27) to ($1.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Quotient is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Quotient is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

2.11 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:QTNT

Previous Symbol

CUSIPN/A

CIK1596946

Webwww.quotientbd.com

Phone011-41-22-716-9800

Employees420

Debt

Debt-to-Equity RatioN/A

Current Ratio4.54

Quick Ratio3.77

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$32.66 million

Price / Sales11.63

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.07) per share

Price / Book-67.29

Profitability

EPS (Most Recent Fiscal Year)($1.44)

Net Income$-102,770,000.00

Net Margins-313.16%

Return on EquityN/A

Return on Assets-49.12%

Miscellaneous

Outstanding Shares80,643,000

Market Cap$379.83 million

Next Earnings Date11/2/2020 (Confirmed)

OptionableOptionable

$4.71

+0.07 (+1.51 %)

(As of 10/23/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive QTNT News and Ratings via Email

Sign-up to receive the latest news and ratings for QTNT and its competitors with MarketBeat's FREE daily newsletter.

Quotient (NASDAQ:QTNT) Frequently Asked Questions

How has Quotient's stock price been impacted by COVID-19?

Quotient's stock was trading at $4.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, QTNT shares have increased by 1.5% and is now trading at $4.71.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Quotient?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Quotient.

When is Quotient's next earnings date?

Quotient is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Quotient.

How can I listen to Quotient's earnings call?

Quotient will be holding an earnings conference call on Monday, November 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Quotient's earnings last quarter?

Quotient Limited (NASDAQ:QTNT) released its earnings results on Monday, August, 3rd. The company reported ($0.32) EPS for the quarter, beating the Zacks' consensus estimate of ($0.33) by $0.01. The business had revenue of $8.92 million for the quarter, compared to analyst estimates of $8.50 million.
View Quotient's earnings history.

What guidance has Quotient issued on next quarter's earnings?

Quotient updated its FY 2021 Pre-Market earnings guidance on Monday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $32-34 million, compared to the consensus revenue estimate of $36 million.

What price target have analysts set for QTNT?

1 equities research analysts have issued 1 year price targets for Quotient's shares. Their forecasts range from $13.50 to $13.50. On average, they anticipate Quotient's share price to reach $13.50 in the next year. This suggests a possible upside of 186.6% from the stock's current price.
View analysts' price targets for Quotient.

Who are some of Quotient's key competitors?

Some companies that are related to Quotient include Intellia Therapeutics (NTLA), Heska (HSKA), Myriad Genetics (MYGN), Lantheus (LNTH), Meridian Bioscience (VIVO), Celldex Therapeutics (CLDX), Aspira Women's Health (AWH), Vermillion (VRML), Oxford Immunotec Global (OXFD), Riot Blockchain (RIOT), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), VolitionRx (VNRX), OncoCyte (OCX) and OncoCyte (OCX).
View all competitors.

What other stocks do shareholders of Quotient own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Verastem (VSTM), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX), Novavax (NVAX), Ocular Therapeutix (OCUL) and Sorrento Therapeutics (SRNE).

Who are Quotient's key executives?

Quotient's management team includes the following people:

Mr. Franz Walt, CEO & Director (Age 61, Pay $2.1M)
Mr. Peter Buhler, Chief Financial Officer (Age 50, Pay $400.99k)
Mr. Edward Farrell, Chief Operating Officer (Age 50, Pay $719.15k)
Mr. Jeremy Stackawitz, Chief Commercial Officer (Age 45, Pay $655.96k)
Mr. Ernest Larnach, Head of Financial Accounting & Treasury (Age 50)

What is Quotient's stock symbol?

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Who are Quotient's major shareholders?

Quotient's stock is owned by many different institutional and retail investors. Top institutional shareholders include First Midwest Bank Trust Division (0.39%), DAVENPORT & Co LLC (0.10%) and FNY Investment Advisers LLC (0.03%). Company insiders that own Quotient stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Roland Boyd.
View institutional ownership trends for Quotient.

Which institutional investors are selling Quotient stock?

QTNT stock was sold by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC. Company insiders that have sold Quotient company stock in the last year include Edward Farrell, and Jeremy Stackawitz.
View insider buying and selling activity for Quotient.

Which institutional investors are buying Quotient stock?

QTNT stock was acquired by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, and FNY Investment Advisers LLC. Company insiders that have bought Quotient stock in the last two years include Frederick Hallsworth, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, and Prondzynski Heino Von.
View insider buying and selling activity for Quotient.

How do I buy shares of Quotient?

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quotient's stock price today?

One share of QTNT stock can currently be purchased for approximately $4.71.

How big of a company is Quotient?

Quotient has a market capitalization of $379.83 million and generates $32.66 million in revenue each year. The company earns $-102,770,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Quotient employs 420 workers across the globe.

What is Quotient's official website?

The official website for Quotient is www.quotientbd.com.

How can I contact Quotient?

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.

This page was last updated on 10/26/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings